Well-deserved recognition for an amazing colleague and friend, @Joshua_Reuss! We share ideas, discuss challenging cases, laugh, and talk about life and family. Work is more meaningful and joyful alongside fantastic colleagues @Joshua_Reuss and @StephenVLiu.

Congratulations to Dr. @Joshua_Reuss on his promotion to Associate Professor of Medicine at @Georgetown University! Such a privilege to work with this rising voice in thoracic oncology.

Congratulations to all of the latest FASCO recipients and a notable shoutout to my fellow co-inductee @ryangentzler! Honored to be inducted together with one of my good friends and former residency mentors. @ASCO

Excited to co-chair the 2026 @HenryFordHealth Thoracic Multidisciplinary Symposium alongside Dr. Andrew Popoff on November 6th at The Dearborn Inn, Michigan! We have an outstanding lineup of national experts joining us to discuss the latest advances in thoracic oncology, from lung cancer screening and early detection to perioperative treatments, molecular biomarkers, and novel therapies for advanced disease. We are especially excited to welcome Dr. @RishiReddy and Dr. @ShirishGadgeel as our keynote speakers, along with an excellent group of speakers from across the country. Looking forward to a day of engaging discussions, multidisciplinary collaboration, and learning from colleagues! 📅 November 6, 2026 📍 The Dearborn Inn, Dearborn, MI 🎓 6 CME credits available Register here: hfhs.cloud-cme.com/thoracic2… @jennifermarksmd @lungoncdoc @chulkimMD @salmanpunekar @radgutta @ChaftJamie @DiFedericoMD #LungCancer #ThoracicOncology #MultidisciplinaryCare #HenryFordHealth #MedEd

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!

Voting for the @ASCO Election is now open 🗳️. I am honored to be running as one of the candidates for the #NominatingCommittee. Visit asco.org/election to learn more about the candidates and place your vote! @CUHKMedicine @apoddc @APCLC_2023 @ctosociety @IASLC @LungPolicy @CUHKofficial

#Voting for @ASCO Election is now open. I am #honored & #humbled to be running as one of the candidates, for the #ASCO #NominatingCommittee, alongside many remarkable talented candidates & GREAT colleagues.   Visit asco.org/election to learn more about the candidates & place your vote!

#ESMO26 Dr. Yilong Wu @ThomasW35874311 presents SANOVO: 1L osimertinib + savolitinib/placebo in EGFR+ NSCLC with MET overexpression. Wow. PFS 24.8 vs 11.1m, HR 0.45 with OS 44.5 vs 34.9m, HR 0.48. RR 81% vs 68%. Toxicities below. Very impressive. #ESMOAmbassadors

🚨 Awaited SAFFRON #ESMO26 OSI + savolitinib vs ChT EGFRm/MET+ NSCLC after 1L OSI. First positive targeted strategy post-progression!👏👏 🔹 PFS: 7.6 vs 5.4 mo (HR 0.55) 🔹 OS: 17.8 vs 12.9 mo (HR 0.68) @NEJM New roads, challenges: biomarker testing IHC/NGS Tx, Liquid in focus!

Just a reminder of the phase III trial landscape and outcomes reported so far with ADC-based combinations in first-line non-oncogene-addicted NSCLC.

#ESMO26 Dr. Wenfeng Fang presents update on OptiTROP-Lung04: sac-TMT (TROP2 ADC) vs platinum + pemetrexed in EGFR mutant NSCLC post TKI therapy. OS favors sac-TMT: 25.9m vs 17.4m, HR 0.69 (even better if 1L was 3G TKI). #ESMOAmbassadors

#ESMO26 Dr. Byoung Cho @cbcbc1971 presents ROSETTA Lung-107: phase 2 pumitamig + docetaxel post-chemoIO in NSCLC. Reassuring safety profile including in squamous NSCLC. In squamous, RR 57%, DCR 100%. In non-squamous, RR 30%, DCR 87%. mPFS 6.9m and 6m PFS 63%. #ESMOAmbassadors

DFS and OS after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial @TheLancet doi.org/10.1016/S0140-6736(2… 👉💯% DFS 👉💯% OS 👏does not need any comment @myESMO @ASCO

The first-line standard of care for ES-SCLC has just changed. The addition of #tarlatamab to chemoimmunotherapy is further changing the disease trajectory of this aggressive disease. A remarkable moment in SCLC treatment.

Grateful to ride in @RideBellRinger to support cancer research at @LombardiCancer together with my father, who is going strong 22+ years with prostate cancer. 💪 🚴

🚨🔥@OncoAlert Hot off the press. Just published @NEJM in conjunction with presentation @myESMO #ESMO26 the long-awaited #PracticeChanging results of: ⭐️#DeLLphi305 phase 3 trial of: ❇️1st line maintenance #Tarlatamab + #Durvalumab) vs #Durvalumab alone in patients with #ExtensiveStage #SmallCell #LungCancer after initial induction Tx with #Chemo + Durvalumab. Study showed: ‼️#Impressive statistically significant & clinically meaningful ⬆️#OverallSurvival Benefit. ✅#mOS: 21.1 vs 12.7 months (HR 0.42) ✅12-month OS: 79.4% vs 53.3% ✅#mPFS: 7.4 vs 1.9 months (HR 0.34) ⚠️ Grade ≥3 #AEs: 46.8% vs 40.6% * In Tarlatamab arm: #CRS: 49.6% (Grade ≥3: 0.4%) #ICANS: 1.1% (Grade ≥3: 0%) 👇🏻 nejm.org/doi/full/10.1056/NE…

#ESMO26 Dr. @bensolomon1 presents ctDNA data from CROWN: 1L lorlatinib in ALK+ NSCLC. Few samples post-progression but no on-target ALK resistance noted, only bypass / off-target. Those with early progression had more baseline mutations. TP53 and clearance were prognostic.

#ESMO26 Dr. Byoung Cho @cbcbc1971 shows simplified dermatologic prophylaxis in COCOON with 1L SC amivantamab + lazertinib for EGFR+ NSCLC had reduction in dermatologic AEs similar to full regimen - this can reduce treatment burden. Lazertinib lead-in for 1 cycle even better.

ABBV-969 dual-targeting ADC #ESMO26 MOA = PSMA/STEAP1— TOPO1 Deep responses in metastatic castration-resistant prostate cancer Surely this one can beat Docetaxel?